News

Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models

Details

Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens. 

Karl Naegler joins Wellington Partners as Managing Partner

Details

Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020. Karl brings to Wellington a strong track record of investments in early and later stage life science companies as well as deep sector knowledge and an extensive global network from over 18 years of industry experience. 

Wellington Partners participates in $53 Million Series B financing at ImCheck

Details

ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ)T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, announced today the closing of a $53 million (€48 million) Series B financing round. The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s first-in-class monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic. 

  1. Wellington Partners participates in $100 Million Series B financing at eGenesis
  2. UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
  3. GTX medical & NeuroRecovery Technologies merge to create leading neurostimulation company for SCI
  4. Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial
© Wellington Partners, 2021.